摘要
目的分析、了解非特指类型EB病毒阳性弥漫大B细胞淋巴瘤(EBV+DLBCL,NOS)的临床病理学特征。方法收集11例EBV+DLBCL,NOS患者,分析其临床特征、组织病理学改变及免疫表型特点。结果 11例EBV+DLBCL,NOS病理组织学主要表现为单一性和多形性两种形态;地图状坏死是多形性形态的组织学特点。免疫组化显示EBV+DLBCL,NOS以non-GCB(非生发中心细胞样型)为主,占72.7%(Hans分型)。EBV+DLBCL,NOS患者预后极差,治疗方案包括R-CHOP、CHOP和COP,所有患者进行随访,3年内已死亡8例,中位生存时间10个月,平均生存时间15个月。结论本组EBV+DLBCL,NOS是有治疗方案和完整临床资料、随访结果和病理学分析研究,该疾病的病理组织学主要表现为单一性和多形性两种形态,免疫表型主要为以non-GCB为主,该病患者治疗效果不佳,预后差。
Objective To analyze the clinicopathological characteristics of EB virus-positive diffuse large B celllymphoma not otherwise specified （EBV＋DLBCL, NOS）. Methods The clinicopathological characteristics and prognosis of 11cases of EBV＋DLBCL,NOS were analyzed. Results There were two morphologic subtypes in 11 EBV＋DLBCL, NOS cases：polymorphic and monomorphic.Polymorphic subtype showed geographic necrosis more frequently than monomorphic subtypedid.According to Hans model, the majority of EBV＋DLBCL, NOS were classified as non-GCB subtype （72.7%）.R-CHOP,CHOP and COP were commonly used chemotherapy regimens. The prognosis of EBP＋DLBCL, NOS was poor, 8 patients in thisseries died within 36 months （1～35 months） with a median survival time of 10 months. Conclusion EBV＋DLBCL,NOS patientspresent with polymorphic and monomorphic patterns.Most patients with the disease were non-GCB subtype and have clinicalaggressiveness and dismal prognosis.
出处
《浙江医学》
CAS
2017年第8期631-634,640,共5页
Zhejiang Medical Journal
基金
宁波市自然科学基金(2012A610200)
